Table 2.
| CRITERIA | Gemmell et al. 2009 | Yurkiw/Mior. 1996 | DeVocht et al. 2003 | Osterbauer et al. 1993 | Wood et al. 2001 | Gemmell et al. 1995 | Schneider et al. 2010 | Shearar et al. 2001 |
|---|---|---|---|---|---|---|---|---|
| ARTICLE | ||||||||
| ASSIGNMENT OF PATIENTS (/9) | 7 | 7 | 5 | 6 | 7 | 7 | 7 | 7 |
| BASELINE VALUES OF GROUPS (/8) | 4 | 4 | 4 | 4 | 4 | 0 | 8 | 4 |
| RELEVANCE OF OUTCOMES & CLINICAL SIGNIFICANCE (/7) | 7 | 7 | 7 | 7 | 7 | 3 | 3 | 7 |
| PROGNOSTIC STRATIFICATION (COMORBIDITY AND RISK FACTORS) (/6) | 6 | 3 | 6 | 3 | 6 | 6 | 6 | 6 |
| BLINDING STRATEGIES (/5) | 3 | 3 | 0 | 0 | 0 | 3 | 0 | 0 |
| CONTAMINATION/CO-INTERVENTION (/4) | 3 | 3 | 3 | 2 | 4 | 3 | 2 | 0 |
| COMPLIANCE OF SUBJECTS TO STUDY PROCEDURES (/4) | 4 | 4 | 3 | 4 | 0 | 3 | 0 | 0 |
| DROP-OUT RATES OF SUBJECTS (/3) | 3 | 2 | 2 | 3 | 0 | 2 | 0 | 0 |
| FOLLOW-UP LEVELS (/2) | 2 | 1 | 0 | 2 | 2 | 0 | 0 | 2 |
| DATE OF PUBLICATION (/2) | 2 | 1 | 2 | 1 | 2 | 1 | 2 | 2 |
| TOTAL (/50) | 41 | 35 | 32 | 32 | 32 | 28 | 28 | 28 |